Drug vignettes: Tocilizumab, CEBM (updated 20th January 2021)

Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are reported to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19.

Source: Current Awareness Service for Health (CASH) - January 22, 2021 Category: Consumer Health News Source Type: news